KYTX (Kyverna Therapeutics) Current Accrued Expense : $20.31 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Current Accrued Expense?

Kyverna Therapeutics's Current Accrued Expense for the quarter that ended in Dec. 2024 was $20.31 Mil.

Kyverna Therapeutics's quarterly Current Accrued Expense increased from Jun. 2024 ($12.03 Mil) to Sep. 2024 ($12.68 Mil) and increased from Sep. 2024 ($12.68 Mil) to Dec. 2024 ($20.31 Mil).

Kyverna Therapeutics's annual Current Accrued Expense increased from Dec. 2022 ($6.25 Mil) to Dec. 2023 ($9.77 Mil) and increased from Dec. 2023 ($9.77 Mil) to Dec. 2024 ($20.31 Mil).

Kyverna Therapeutics Current Accrued Expense Historical Data

The historical data trend for Kyverna Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Current Accrued Expense Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

6.63

6.25

9.77

20.31

Kyverna Therapeutics Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Current Accrued Expense	Get a 7-Day Free Trial					9.77	9.33	12.03	12.68	20.31

Kyverna Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Kyverna Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.